ONS-5010 for neovascular age-related macular degeneration

ONS-5010 is an ophthalmic formulation of bevacizumab under development to be administered as an intravitreal injection for the treatment of wet/neovascular age-related macular degeneration (nAMD). nAMD is a retinal condition that can cause deterioration of vision. nAMD affects the middle of the vision in one or both eyes, and often initially presents with blurred or distorted central vision, but symptoms can also include seeing straight lines as wavy, objects looking smaller than usual, changes in colours, hallucinations and if untreated can progress to blindness. Despite high off-label use, there are currently no licenced ophthalmic formulations of bevacizumab for the treatment of nAMD.